Eisai first quarter results story – correction
This article was originally published in Scrip
Executive Summary
The title of the August 1st Scrip Online story on Eisai's first quarter results should have read: "MGI boost for Eisai, but rabeprazole languishes", not "MGI boost for Eisai but lansoprazole languishes". Rabeprazole should also have been substituted for lansoprazole in the fourth paragraph of the story, which referred to the development of over-the-counter versions of the product.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.